BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Freiman JM, Wang J, Easterbrook PJ, Horsburgh CR, Marinucci F, White LF, Kamkamidze G, Krajden M, Loarec A, Njouom R, Nguyen KV, Shiha G, Soliman R, Solomon SS, Tsertsvadze T, Denkinger CM, Linas B. Deriving the optimal limit of detection for an HCV point-of-care test for viraemic infection: Analysis of a global dataset. J Hepatol 2019;71:62-70. [PMID: 30797050 DOI: 10.1016/j.jhep.2019.02.011] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 3.7] [Reference Citation Analysis]
Number Citing Articles
1 Marcellusi A, Mennini FS, Ruf M, Galli C, Aghemo A, Brunetto MR, Babudieri S, Craxi A, Andreoni M, Kondili LA. Optimizing diagnostic algorithms to advance Hepatitis C elimination in Italy: A cost effectiveness evaluation. Liver Int 2021. [PMID: 34582627 DOI: 10.1111/liv.15070] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
2 Lamoury FMJ, Njouom R, Amougou-Atsama M, Yiagnigni Mfopou E, Berishvili N, Sologashvili M, Fajardo E, Malobela A, Macé A, Chirehwa M, Alkhazashvili M, Ivanova Reipold E. Diagnostic Performance and Usability of the Genedrive® HCV ID Kit in Two Decentralized Settings in Cameroon and Georgia. Diagnostics (Basel) 2021;11:746. [PMID: 33921930 DOI: 10.3390/diagnostics11050746] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
3 Morgan JR, Savinkina A, Pires Dos Santos AG, Xue Z, Shilton S, Linas B. HCV Viral Load Greater Than 1000 IU/ml at Time of Virologic Failure in Direct-Acting Antiviral-Treated Patients. Adv Ther 2021;38:1690-700. [PMID: 33590445 DOI: 10.1007/s12325-021-01647-4] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
4 Catlett B, Bajis S, Starr M, Dore GJ, Hajarizadeh B, Cunningham PH, Applegate TL, Grebely J. Evaluation of the Aptima HCV Quant Dx Assay for Hepatitis C Virus RNA Detection from Fingerstick Capillary Dried Blood Spot and Venepuncture-Collected Samples. J Infect Dis 2021;223:818-26. [PMID: 32710758 DOI: 10.1093/infdis/jiaa442] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
5 Berg MG, Olivo A, Forberg K, Harris BJ, Yamaguchi J, Shirazi R, Gozlan Y, Sauleda S, Kaptue L, Rodgers MA, Mor O, Cloherty GA. Advanced molecular surveillance approaches for characterization of blood borne hepatitis viruses. PLoS One 2020;15:e0236046. [PMID: 32678844 DOI: 10.1371/journal.pone.0236046] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
6 Chevaliez S, Wlassow M, Volant J, Roudot-Thoraval F, Bachelard A, Poiteau L, Trabut JB, Hézode C, Bourdel A, Dominguez S. Assessing Molecular Point-of-Care Testing and Dried Blood Spot for Hepatitis C Virus Screening in People Who Inject Drugs. Open Forum Infect Dis 2020;7:ofaa196. [PMID: 32617372 DOI: 10.1093/ofid/ofaa196] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 3.0] [Reference Citation Analysis]
7 Ma J, Ren Y, He L, He X, Xing W, Jiang Y. An efficient method for simultaneously screening for HIV, syphilis, and HCV based on one dried blood spot sample. Antiviral Res 2020;181:104775. [PMID: 32246944 DOI: 10.1016/j.antiviral.2020.104775] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
8 Mohamed Z, Mbwambo J, Rwegasha J, Mgina N, Doulla B, Mwakale P, Tuaillon E, Chevaliez S, Shimakawa Y, Taylor-Robinson SD, Thursz MR, Brown AS, Lemoine M. In-field evaluation of Xpert® HCV viral load Fingerstick assay in people who inject drugs in Tanzania. Liver Int 2020;40:514-21. [PMID: 31778282 DOI: 10.1111/liv.14315] [Cited by in Crossref: 8] [Cited by in F6Publishing: 17] [Article Influence: 2.7] [Reference Citation Analysis]
9 Saludes V, Antuori A, Folch C, González N, Ibáñez N, Majó X, Colom J, Matas L, Casabona J, Martró E; HepCdetect II Study Group. Utility of a one-step screening and diagnosis strategy for viremic HCV infection among people who inject drugs in Catalonia. Int J Drug Policy 2019;74:236-45. [PMID: 31706159 DOI: 10.1016/j.drugpo.2019.10.012] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 4.0] [Reference Citation Analysis]
10 Valencia J, Alvaro-Meca A, Troya J, Cuevas G, Gutiérrez J, Morro A, Alvarez J, Pulido L, Cañamares I, Escobar I, Moreno S, Ryan P. High rates of early HCV reinfection after DAA treatment in people with recent drug use attended at mobile harm reduction units. Int J Drug Policy 2019;72:181-8. [PMID: 31253391 DOI: 10.1016/j.drugpo.2019.06.016] [Cited by in Crossref: 11] [Cited by in F6Publishing: 14] [Article Influence: 3.7] [Reference Citation Analysis]
11 Spearman CW, Dusheiko GM, Hellard M, Sonderup M. Hepatitis C. Lancet. 2019;394:1451-1466. [PMID: 31 DOI: 10.1016/s0140-6736(19)32320-7] [Cited by in Crossref: 108] [Cited by in F6Publishing: 151] [Article Influence: 2.3] [Reference Citation Analysis]